Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker ... It plans to submit orforglipron for FDA approval for obesity in Q4, and for type 2 diabetes in the first half of 2026.

It plans to submit orforglipron for FDA approval for obesity in Q4, and for type 2 diabetes ... On the day of Eli Lilly's earnings report, CVS Health announced that its pharmacy benefit manager ...

Tiger Global's tech-focused portfolio hits $26.59B with Meta, Microsoft, and Amazon leading. Discover new positions and ...

Hims & Hers Health, Inc. navigates strong growth and partnerships despite rising competitive risks. Click here to read an ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... number of billionaire investors, updated as of Q4 2024. All of these billionaire investors are founders ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... with the highest number of hedge fund holders as of Q4 2024. We sourced the hedge fund sentiment data from ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best income stocks. Amid concerns over trade restrictions and a weakening economy ...

May 12 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Sunday its drug Zepbound was superior to Novo Nordisk's (NOVOb.CO), opens new tab Wegovy across five weight-loss targets such as ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. However, the guidance ...